Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of intermittent pneumatic compression on intracranial pressure in postoperative patients with severe traumatic brain injury.

The Journal of international medical research·2026
Same author

Joule-heating synthesis of high-entropy oxides as efficient catalysts for electrochemical methanol oxidation.

Chemical communications (Cambridge, England)·2026
Same author

Mesonephric-like adenocarcinoma of the uterine corpus: a case report.

Frontiers in medicine·2026
Same author

WNT4 reprograms dental pulp stem cells to resist PANoptosis and rebuild neurogenic potential for facial nerve injury repair.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Monte Carlo investigation of spatiotemporal distortions in attosecond soft X-ray pulse focusing using a two-stage toroidal mirror system.

Optics express·2026
Same author

Multimodal interventional bronchoscopy for chronic pulmonary <i>Aspergillus</i> infection with post-tubercular bronchial occlusion: a case report.

Frontiers in medicine·2026

Related Experiment Video

Updated: Jun 10, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With

Bing Xue1, Yue Bai1,2, Wu-Di Yang1,3

  • 1Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, China.

IET Systems Biology
|June 8, 2026
PubMed
Summary

Researchers identified an anoikis-related gene signature to predict prognosis in triple-negative breast cancer (TNBC). This signature may also indicate how patients respond to immunotherapy, offering new avenues for TNBC treatment.

Keywords:
bioinformaticsgenomicspatient treatmenttumours

Related Experiment Videos

Last Updated: Jun 10, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Area of Science:

  • Oncology
  • Genomics
  • Cancer Metastasis

Background:

  • Triple-negative breast cancer (TNBC) is aggressive with poor prognosis and limited therapies.
  • Anoikis resistance is crucial for TNBC metastasis and treatment resistance.
  • Anoikis-related molecular signatures for TNBC prognosis are not well-characterized.

Purpose of the Study:

  • To identify and characterize anoikis-related molecular signatures for prognostic prediction in TNBC.
  • To develop a gene signature that integrates single-cell and bulk transcriptomic data.
  • To evaluate the association of the signature with immune features and immunotherapy response.

Main Methods:

  • Analysis of bulk RNA-seq data (TCGA-TNBC, GSE58812) and single-cell transcriptomic data.
  • Identification of anoikis-related genes using WGCNA and single-cell module scoring.
  • Construction of a prognostic signature via Cox and LASSO regression; validation of STC2.

Main Results:

  • An anoikis-related gene signature (ASS1, COL18A1, STC2, DHX36, S100B, TGFBI) was established.
  • High-risk patients showed poor survival, increased cancer-associated fibroblast infiltration, and reduced T-cell infiltration.
  • Low STC2 expression correlated with poor prognosis; STC2 knockdown reduced anoikis-related apoptosis in vitro.

Conclusions:

  • An anoikis-related gene signature can improve prognostic stratification in TNBC.
  • The signature reflects immunotherapy-related features, potentially guiding treatment strategies.
  • STC2 is a potential prognostic biomarker and therapeutic target in TNBC.